Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)

NCT05084989 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

948

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

BIOLOGICAL: Part1:Recombinant two-component COVID-19 vaccine (CHO cell)
BIOLOGICAL: Part1: Placebo
BIOLOGICAL: Part2: Recombinant two-component COVID-19 vaccine (CHO cell)
BIOLOGICAL: Part2: COVID-19 Vaccine, mRNA

Sponsor

Jiangsu Rec-Biotechnology Co., Ltd.